195 related articles for article (PubMed ID: 38480275)
1. Upregulation of HLA-II related to LAG-3
Guo W; Peng D; Liao Y; Lou L; Guo M; Li C; Yu W; Tian X; Wang G; Lv P; Zuo J; Shen H; Li Y
Cancer Sci; 2024 May; 115(5):1388-1404. PubMed ID: 38480275
[TBL] [Abstract][Full Text] [Related]
2. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
Front Immunol; 2021; 12():637146. PubMed ID: 34025646
[TBL] [Abstract][Full Text] [Related]
3. 4-1BB Agonism Averts TIL Exhaustion and Licenses PD-1 Blockade in Glioblastoma and Other Intracranial Cancers.
Woroniecka KI; Rhodin KE; Dechant C; Cui X; Chongsathidkiet P; Wilkinson D; Waibl-Polania J; Sanchez-Perez L; Fecci PE
Clin Cancer Res; 2020 Mar; 26(6):1349-1358. PubMed ID: 31871298
[TBL] [Abstract][Full Text] [Related]
4. Single-Cell Atlas Reveals Complexity of the Immunosuppressive Microenvironment of Initial and Recurrent Glioblastoma.
Fu W; Wang W; Li H; Jiao Y; Huo R; Yan Z; Wang J; Wang S; Wang J; Chen D; Cao Y; Zhao J
Front Immunol; 2020; 11():835. PubMed ID: 32457755
[TBL] [Abstract][Full Text] [Related]
5. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
[TBL] [Abstract][Full Text] [Related]
6. IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4(+) T cells.
Ohno Y; Kitamura H; Takahashi N; Ohtake J; Kaneumi S; Sumida K; Homma S; Kawamura H; Minagawa N; Shibasaki S; Taketomi A
Cancer Immunol Immunother; 2016 Feb; 65(2):193-204. PubMed ID: 26759006
[TBL] [Abstract][Full Text] [Related]
7. Local Targeting of NAD
Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
Lamano JB; Lamano JB; Li YD; DiDomenico JD; Choy W; Veliceasa D; Oyon DE; Fakurnejad S; Ampie L; Kesavabhotla K; Kaur R; Kaur G; Biyashev D; Unruh DJ; Horbinski CM; James CD; Parsa AT; Bloch O
Clin Cancer Res; 2019 Jun; 25(12):3643-3657. PubMed ID: 30824583
[TBL] [Abstract][Full Text] [Related]
9. Blocking Wnt/β-catenin Signal Amplifies Anti-PD-1 Therapeutic Efficacy by Inhibiting Tumor Growth, Migration, and Promoting Immune Infiltration in Glioblastomas.
Zhang H; Bi Y; Wei Y; Liu J; Kuerban K; Ye L
Mol Cancer Ther; 2021 Jul; 20(7):1305-1315. PubMed ID: 34001635
[TBL] [Abstract][Full Text] [Related]
10. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
[TBL] [Abstract][Full Text] [Related]
11. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition.
Karachi A; Yang C; Dastmalchi F; Sayour EJ; Huang J; Azari H; Long Y; Flores C; Mitchell DA; Rahman M
Neuro Oncol; 2019 Jun; 21(6):730-741. PubMed ID: 30668768
[TBL] [Abstract][Full Text] [Related]
12. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
[TBL] [Abstract][Full Text] [Related]
13. Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma.
Simonds EF; Lu ED; Badillo O; Karimi S; Liu EV; Tamaki W; Rancan C; Downey KM; Stultz J; Sinha M; McHenry LK; Nasholm NM; Chuntova P; Sundström A; Genoud V; Shahani SA; Wang LD; Brown CE; Walker PR; Swartling FJ; Fong L; Okada H; Weiss WA; Hellström M
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083417
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.
Johnson DB; Nixon MJ; Wang Y; Wang DY; Castellanos E; Estrada MV; Ericsson-Gonzalez PI; Cote CH; Salgado R; Sanchez V; Dean PT; Opalenik SR; Schreeder DM; Rimm DL; Kim JY; Bordeaux J; Loi S; Horn L; Sanders ME; Ferrell PB; Xu Y; Sosman JA; Davis RS; Balko JM
JCI Insight; 2018 Dec; 3(24):. PubMed ID: 30568030
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8
Park J; Kwon M; Kim KH; Kim TS; Hong SH; Kim CG; Kang SG; Moon JH; Kim EH; Park SH; Chang JH; Shin EC
Clin Cancer Res; 2019 Apr; 25(8):2549-2559. PubMed ID: 30659023
[TBL] [Abstract][Full Text] [Related]
16. Aging- and Tumor-Mediated Increase in CD8
Huff WX; Bam M; Shireman JM; Kwon JH; Song L; Newman S; Cohen-Gadol AA; Shapiro S; Jones T; Fulton K; Liu S; Tanaka H; Liu Y; Wan J; Dey M
Immunohorizons; 2021 Jun; 5(6):395-409. PubMed ID: 34103370
[TBL] [Abstract][Full Text] [Related]
17. Blockade of PD-1 and LAG-3 Immune Checkpoints Combined with Vaccination Restores the Function of Antiviral Tissue-Resident CD8
Roy S; Coulon PG; Prakash S; Srivastava R; Geertsema R; Dhanushkodi N; Lam C; Nguyen V; Gorospe E; Nguyen AM; Salazar S; Alomari NI; Warsi WR; BenMohamed L
J Virol; 2019 Sep; 93(18):. PubMed ID: 31217250
[TBL] [Abstract][Full Text] [Related]
18. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.
Yanik EL; Kaunitz GJ; Cottrell TR; Succaria F; McMiller TL; Ascierto ML; Esandrio J; Xu H; Ogurtsova A; Cornish T; Lipson EJ; Topalian SL; Engels EA; Taube JM
JAMA Oncol; 2017 Jul; 3(7):974-978. PubMed ID: 28334399
[TBL] [Abstract][Full Text] [Related]
19. Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes.
Mohme M; Schliffke S; Maire CL; Rünger A; Glau L; Mende KC; Matschke J; Gehbauer C; Akyüz N; Zapf S; Holz M; Schaper M; Martens T; Schmidt NO; Peine S; Westphal M; Binder M; Tolosa E; Lamszus K
Clin Cancer Res; 2018 Sep; 24(17):4187-4200. PubMed ID: 29444930
[No Abstract] [Full Text] [Related]
20. T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma.
Woroniecka K; Chongsathidkiet P; Rhodin K; Kemeny H; Dechant C; Farber SH; Elsamadicy AA; Cui X; Koyama S; Jackson C; Hansen LJ; Johanns TM; Sanchez-Perez L; Chandramohan V; Yu YA; Bigner DD; Giles A; Healy P; Dranoff G; Weinhold KJ; Dunn GP; Fecci PE
Clin Cancer Res; 2018 Sep; 24(17):4175-4186. PubMed ID: 29437767
[No Abstract] [Full Text] [Related]
[Next] [New Search]
